Survival gains seen with rituximab and mycophenolate in RA lung disease

LIVERPOOL, ENGLAND – Rituximab and mycophenolate mofetil could offer patients with rheumatoid arthritis and concomitant interstitial lung disease a survival advantage over other therapies, according...

Field of Interest: Rheumatology